AB Science reports its revenues for the year 2022 and provides an
update on its activities
PRESS
RELEASE
AB SCIENCE PRESENTS ITS
FINANCIAL INFORMATION AS OF DECEMBER 31,
2022 AND
THE KEY EVENTS OF THE PERIOD
-
Financial information and other corporate
information
- Consolidated
operating loss of €15.9 million as of 31 December 2022, compared
with a loss of €13.8 million as of 31 December 2021, an increase of
the operating loss of €2.1 million (15.4%)
-
Cash position of €7.3 million as of 31 December 2022, plus a cash
contribution of €11.5 million as part of the capital increase
completed in April 2023, plus the €7.1 million of 2020 and 2021
research tax credit and €6.0 million for drawdown in January 2023
of the second tranche under the financing agreement with the
European Investment Bank
- Capital increase
for an amount of €15 million completed in April 2023, of which
€11.5 million in cash and €3.5 million in debt compensation
- Drawdown of the
two tranches (December 2022 and January 2023) under the financing
agreement with the European Investment Bank for a total amount of
€12 million
- Renewal of the Programme
d’Augmentation de Capital à Terme concluded by AB Science with
Alpha Blue Ocean
(Investors are invited to take note of the risks
associated with this potentially dilutive transaction, which could
create downward pressure on the AB Science share, as mentioned in
sections 6.4.4 and 6.4.6 of the 2022 annual report).
-
Clinical development
- Focus of the
development strategy on amyotrophic lateral sclerosis with the
masitinib platform and on the second microtubule platform and
seeking licensing agreements for non-rare disease indications of
masitinib
- Filing of a
marketing authorization application for masitinib in the treatment
of amyotrophic lateral sclerosis (ALS) in Canada, under the Notice
of Compliance with Conditions (NOC/c) policy and response to the
Notice of Deficiency (NOD)
- Filing of a
conditional marketing authorization application to the European
Medicines Agency (EMA) for masitinib in the treatment of
amyotrophic lateral sclerosis (ALS) and response to the Day 120
assessment of the procedure in April 2023
- Approval of both
confirmatory Phase 3 studies with masitinib in progressive forms of
multiple sclerosis and Alzheimer's disease in Europe and in the
US
- First complete
bone marrow response in an acute myeloid leukemia patient in its
AB8939 Phase I/II clinical trial
Paris, 28 April 2023, 6.30pm CET
AB Science SA (Euronext -
FR0010557264 - AB) today reports its revenues for the year 2022 and
provides an update on its activities.
CLINICAL DEVELOPMENT KEY EVENTS
DURING THE YEAR
2022 AND SINCE
DECEMBER 31,
2022
Focus of the
development strategy on amyotrophic lateral sclerosis with
the masitinib platform and on the
second microtubule platform and seeking licensing
agreements for non-rare disease indications
of masitinib
On 21 April 2023, AB Science announced its
decision to focus its development strategy as follows:
-
Allocation of current resources primarily to the development of
masitinib for the treatment of amyotrophic lateral sclerosis and
the development of the microtubule destabilizer agents (MDA)
platform, with the clinical development of AB8939 in refractory
acute myeloid leukemia and the initiation of regulatory preclinical
development of a new oral molecule in the same microtubule class
for sarcoma and solid tumors.
AB Science wants to focus the majority of our
clinical resources on the development of rare diseases with
masitinib, on the development of the microtubule platform with
AB8939 and future molecules of the same family due to the very
encouraging first results.
-
Acceleration of the process of seeking a license for masitinib in
non-rare disease indications, with priority given to progressive
forms of multiple sclerosis and Alzheimer's disease.
This acceleration is possible now that the
confirmatory Phase 3 studies have been approved by the FDA in the
United States and the major European agencies. To this end, the
Company has retained the services of a leading investment bank.
This license search is a priority in the
Company's strategy, given the number of clinical studies already
conducted and the maturity of the pipeline, and given the
additional investments required to complete the clinical program,
up to market authorizations. We want to highlight that the duration
of this license search is not predictable and that the realization
of a license is dependent on a number of factors and is not
guaranteed. However, the milestones reached at this stage are
essential factors that contribute to the feasibility of this
strategy.
As a result of the focus strategy, AB Science
has decided to adapt its organization, which should lead to a
significant reduction in costs. AB Science has therefore filed a
redundancy plan to the authorities, aiming to cut a maximum of 41
jobs (out of a total of 100 employees).
This strategic focus reinforces and sustains the
existing agreement between certain shareholders of AB Science and
Alain Moussy.
Filing of a
marketing authorization
application for masitinib
in the treatment of amyotrophic lateral
sclerosis (ALS) in Canada, under the Notice of Compliance with
Conditions (NOC/c) policy
AB Science announced in February 2022 that
Health Canada has granted authorization to file a New Drug
Submission for masitinib in the treatment of amyotrophic lateral
sclerosis (ALS) under the Notice of Compliance with Conditions
(NOC/c) policy. AB Science subsequently announced on May 26, 2022
that Health Canada had issued a favorable opinion on the
preliminary review of the dossier and that the review of the
dossier had started.
This assessment was made based on a
pre-submission package sent by AB Science including, efficacy data
of study AB10015, long-term survival data (75 months average
follow-up from diagnosis) of study AB10015, and safety data.
In December 2022, AB Science announced that it
has received a Notice of Deficiency (“NOD”) from Health Canada.
This NOD means that Health Canada has requested the provision of
additional information related to masitinib New Drug Submission.
Initially, AB Science had 90 days to respond to this NOD, but
because EMA and Health Canada regulatory procedures were concurrent
and in order to ensure the best quality of responses in both
procedures, AB Science, in agreement with Health Canada, has
extended the response period to Health Canada by 30 days. AB
Science responded to this NOD.
If granted, an NOC/c is authorization to market
a drug with conditions. Such conditions will be discussed with
Health Canada during the procedure.
An estimated 3,000 Canadians are currently
living with ALS. Each year approximately 1,000 Canadians die from
ALS. A similar number of Canadians are diagnosed with ALS each
year.
Filing of a conditional
marketing authorization
application to the European Medicines Agency (EMA)
for masitinib in the treatment of
amyotrophic lateral sclerosis (ALS)
AB Science announced in August 2022 that it has
filed an application for conditional Marketing Authorization to the
European Medicines Agency (EMA) for masitinib in the treatment of
amyotrophic lateral sclerosis (ALS). The application is based on
results from the phase 2/3 AB10015 study and its long-term survival
follow-up. Study AB10015 was a randomized, double-blind,
placebo-controlled trial over a 48-week treatment period, conducted
with 394 ALS patients and evaluating Alsitek in combination with
riluzole versus riluzole alone.
This application has been validated by EMA and
review by the Committee for Medicinal Products for Human Use (CHMP)
has begun. The CHMP has a target of 210 active evaluation days to
review the application.
In April 2023, AB Science announced it has
submitted its responses to the Day 120 assessment of the
procedure.
Approval of confirmatory Phase 3 study
with masitinib in
progressive forms of multiple
sclerosis
AB Science announced in January 2022 that it has
been authorized by the French Medicine Agency, ANSM, to initiate a
Phase III study (AB20009) evaluating masitinib in patients with
Primary Progressive Multiple Sclerosis (PPMS) or non-active
Secondary Progressive Multiple Sclerosis (nSPMS).
This study has also been approved by several
European agencies as well as by the US Food and Drug Administration
(FDA).
The study will enroll 800 patients from numerous
study centers with Expanded Disability Status Scale (EDSS) score
between 3.0 to 6.0 and absence of T1 Gadolinium-enhancing brain
lesions as measured by magnetic resonance imaging (MRI).
The primary objective of the study will be to
evaluate the effect of masitinib on time to confirmed disability
progression, with progression defined as 1-point worsening when
EDSS baseline score ≤5.5, or 0.5 if baseline score >5.5 from
randomization to week 96.
This confirmatory study follows successful
completion of a first Phase 2B/3 study (AB07002) in primary
progressive (PPMS) and non-active secondary progressive (nSPMS)
multiple sclerosis. This study met its primary analysis endpoint,
demonstrating a statistically significant reduction in cumulative
change on EDSS with masitinib 4.5 mg/kg/day (p=0.0256).
Approval of confirmatory Phase 3 study
with masitinib in Alzheimer's
disease
AB Science announced in October 2022 that the
first authorizations have been received to initiate its phase 3
confirmatory study (AB21004) evaluating masitinib in patients with
mild to moderate Alzheimer's Disease (AD) from the French Medicine
Agency (ANSM) together with AEMPS (Spain agency) and EOF (Greece
agency).
This study has also been approved by the US Food
and Drug Administration (FDA).
Study AB21004 is a randomized, double-blind
phase 3 study to evaluate the safety and efficacy of masitinib in
patients with mild to moderate Alzheimer's disease, as an add-on
therapy to standard of care, cholinesterase inhibitors and/or
memantine. The study will enroll 600 patients with confirmed
clinical diagnosis of mild and moderate Alzheimer's disease,
corresponding to an Activities of Daily Living (ADCS-ADL) score of
less than 73 and a Mini Mental State Examination (MMSE) score of
between 14 to 25, inclusive.
The objective of study AB21004 is to confirm
treatment effect with masitinib 4.5 mg/kg/day as an adjunct to
cholinesterase inhibitor and/or memantine in patients with
mild-to-moderate Alzheimer's disease. The primary endpoint of the
study will be to evaluate the effect of masitinib on absolute
change from baseline in ADCS-ADL score and in ADAS-Cog-11.
This confirmatory study follows a first positive
Phase 2B/3 study (AB09004) which showed that masitinib can generate
a significant treatment effect relative to placebo in the primary
endpoint of change from baseline in ADAS-Cog, an instrument that
measures the effect on cognition and memory.
First complete bone marrow response in
an acute myeloid leukemia
patient in its AB8939 Phase I/II clinical
trial
AB Science announced in March 2023 a case report
from the initial stage of its Phase I/II study (AB18001) evaluating
AB8939, a microtubule destabilizer, in patients with refractory and
relapsed acute myeloid leukemia (AML).
The AML patient in question was in failure to
prior treatment with azacitidine and presented with a MECOM gene
rearrangement, which is a biomarker for resistance to standard
chemotherapies that is associated with a high-risk of disease
progression and inferior prognosis.
One month after the first treatment cycle (i.e.,
three consecutive days of AB8939 treatment) there was a drastic
reduction in bone marrow blast cells (i.e., leukemia cells), from a
pretreatment level of 55% to 5% (i.e., a morphologic leukemia free
state). Remarkably, this response was achieved at a very low dose
of AB8939, corresponding to the second step of dose increment (out
of 13 potential steps) in phase I. The patient also showed
excellent tolerance to AB8939, having experienced no
treatment-related toxicities. At the request of the investigator,
AB Science has authorized further treatment cycles of AB8939 to
this patient. One month after the second treatment cycle of three
consecutive days at this dose, a good response has been maintained
with bone marrow blasts being at 10% (corresponding to a 5-fold
reduction relative to baseline). A third treatment cycle for this
patient has been initiated.
Considering the overall study to date, there
have been no signs of moderate, severe or serious toxicity and
approximately 50% of patients have requested further treatment
cycles of AB8939 after the first cycle of treatment and a
measurement at day 28.
CONSOLIDATED FINANCIAL INFORMATION FOR
THE YEAR 2022
The operating result at 31 December 2022 was a
loss of €15,937k, compared with a loss of €13,808k as of 31
December 2021, an increase in the operating loss of €2,129k
(15.4%).
- Operating income,
exclusively made up of revenues related to the operation of a drug
in veterinary medicine, amounted to €958k as of 31 December 2022,
compared to €1,607k a year earlier.
- Operating expenses
amounted to €16,896k as of 31 December 2022, compared to €15,415k
as of 31 December 2021, an increase of 9.6%.
- Marketing expenses
were stable compared to 31 December 2021, rising from €493k at 31
December 2021 to €480k as of 31 December 2022.
- Administrative
expenses decreased by 15% from €3,578k as of 31 December 2021 to
€3,040k as of 31 December 2022.
- Research and
development costs increased by €2,112k, or 18.8%, from €11,233k as
of 31 December 2021 to €13,345k as of 31 December 2022.
The gain of €2,326k at 31 December 2022 is
mainly related to the recognition of the change in fair value
between 31 December 2022 and 31 December 2021 of the preference
shares resulting from the conversion of the bonds in December 2016
(class C), i.e. a financial gain of €2,557k with no impact on cash
for the period.
The consolidated net loss at 31 December 2022 is
€13,615k compared to a loss of €14,463k as of 31 December 2021, a
decrease of 5.9%.
The following table summarizes the consolidated
financial statements for the year 2022 prepared in accordance with
IFRS, and comparative information with the year 2021:
In thousands of euros, except for share data |
31/12/2022 |
31/12/2021 |
Net turnover |
958 |
1 607 |
Cost of sales |
(31) |
(111) |
Marketing expenses |
(480) |
(493) |
Administrative expenses |
(3,040) |
(3,578) |
Research and development expenses |
(13,345) |
(11,233) |
Operating
income |
(15,937) |
(13,808) |
Financial income |
4,904 |
887 |
Financier expenses |
(2,578) |
(1,506) |
Financial
income |
2,326 |
(618) |
Net
income |
(13,615) |
(14,463) |
Total comprehensive income for the period |
(13,356) |
(14,189) |
Basic earnings per share - in euros |
(0,29) |
(0,30) |
Diluted earnings per share - in euros |
(0,29) |
(0,30) |
In thousands of euros |
31/12/2022 |
31/12/2021 |
Cash and cash equivalents |
7,269 |
8,721 |
Total Assets |
23,841 |
21,271 |
Equity |
(35,670) |
(23,198) |
Non-current liabilities |
36,432 |
26,986 |
Trade payables |
12,248 |
11,368 |
Current liabilities |
23,079 |
17,482 |
OTHER
CORPORATE INFORMATION FOR YEAR 2022 AND SINCE DECEMBER 31,
2022
Capital increase for an amount of 15
million euros
AB Science announced on April 24, 2023 the
success of its capital increase through the issuance of new
ordinary shares with attached warrants, with a waiver of
preferential subscription rights.
The Capital Increase consisted of a private
placement pursuant to Articles L. 225-136 of the French Commercial
Code and L. 411-2 1° of the French Monetary and Financial Code and
has been carried out with a waiver of preferential subscription
rights, pursuant to the delegation of authority granted to the
Board of Directors under the 20th resolution of the Combined
General Shareholders’ Meeting of June 29, 2022. The Capital
Increase has taken the form of the issuance of 2,608,686 actions
new ordinary shares (the “New Shares”) to each of which are
attached a share subscription warrant (the “Warrants”).
The Capital Increase was made through a cash
contribution of approximately EUR 11.5 million and by offsetting
existing receivables, i.e. approximately EUR 3.0 million
(receivables related to the pre-financing of the research tax
credit for the 2020 financial year and maturing in 2023, as well as
approximately EUR 500,000 in interest accrued to date on the
convertible bonds issued in February 2022).
Two warrants giving the right to subscribe to
one ordinary share, all of the 2,608,686 New Shares and all of the
1,304,343 new shares that would be issued upon exercise of the
warrants, i.e. a total of 3,913,029 shares in the Company,
represent 7.36% of the Company's current share capital.
The issue price of the New Shares has been set
at 5.75 euros (0.01 euro par value and 5.74 euros issue premium)
and the exercise price of the Warrants at 8.625 euros, representing
a total fundraising of approximately EUR 15.0 million (taking into
account the exercise of the warrants, the maximum amount of the
Capital Increase could be increased by an amount of 26.3 million
euros).
The Warrants may be exercised from January 1st,
2025 to December 31, 2030.
Drawdown of the first two tranches for a
total amount of €12 million under its financing agreement with the
European Investment Bank
AB Science announced in December 2022 that it
has received payment of €6.0 million as the first tranche of a €15
million loan from the European Investment Bank (EIB).
AB Science announced in January 2023 that it has
received payment of €6.0 million as the second tranche of the EIB
loan.
The agreement signed with the EIB provides a
financing in two tranches of EUR 6.0 million and a third tranche of
EUR 3.0 million, each subject to the fulfillment of certain
conditions precedent, which have been satisfied for the first two
tranches. Each tranche is accompanied by the issue of warrants, the
number of which is calculated in relation to a reference price of
14 euros according to the following formula : Number of warrants =
Amount of the tranche / (14 x m) with m = 3.4 for tranche 1 and 3.7
for tranche 2.
The first tranche has a maturity of six years
and is therefore repayable in December 2028. It carries a
capitalized annual interest rate of 9.0% and the issuance of
126,050 warrants, each giving the right to subscribe to one
ordinary share of AB Science at 8.61 euros for 15 years. These
warrants represent 0.24% of the current capital of the Company (if
they were to be exercised in their entirety).
The second tranche, also of EUR 6.0 million, has
a maturity of five years and is therefore repayable in January
2028. It carries a capitalized annual interest rate of 7.0% and the
issuance of 115,830 warrants, each giving the right to subscribe to
one ordinary share of AB Science at 14.0 euros for 15 years. These
warrants represent 0.22% of the current capital of the Company (if
they were to be exercised in their entirety).
Renewal of the
Programme d’Augmentation
de Capital à Terme
(PACT)
concluded with Alpha Blue
Ocean
Alpha Blue Ocean is committed to subscribe, from
the date of publication of the 2022 annual report, to newly issued
shares of AB Science (in tranches comprised of a number of shares
between 500,000 and 1 million) over a period of 24 months, up to a
maximum of 4.0 million shares in total (or 7.2% of the company’s
share capital on the basis of the capital after the capital
increase announced on 24 April 2023). Such subscriptions for new
shares shall be carried out using the 28th resolution of the
Shareholder’s Meeting of June 29, 2022 (as renewed or otherwise
amended, if applicable).
By way of example, based on the April 27, 2023
closing price of AB Science’s shares, i.e 6.27 euros, on Euronext
Paris, it is estimated that AB Science could raise approximately 25
million euros through this equity financing facility.
For each tranche, the issuance price of new
shares of AB Science, subscribed by Alpha Blue Ocean, shall be
equal to 100% of the volume-weighted average price of the shares of
AB Science traded on Euronext Paris over the three trading days
preceding a tranche drawdown request.
For each tranche, and after the
settlement-delivery of the new shares of AB Science following the
relevant capital increase, 80% of the proceeds of the tranche shall
be secured in an escrow account with a third-party escrow agent.
The remaining balance shall be kept by AB Science.
Following predefined trading rules for each
tranche, Alpha Blue Ocean shall manage the orderly sale, on or off
the market, of the AB Science shares subscribed to. 95% of the
proceeds shall be distributed to AB Science on a monthly basis
(minus a structuration fee), directly from Alpha Blue Ocean or by
way of a release from the escrow account.
AB Science has no obligations to draw down on
the PACT and shall utilise this innovative financing solution only
if necessary and if the market conditions are favourable to the
interests of AB Science and its shareholders.
For each drawdown, the number of shares issued
with respect to this agreement and admitted to trading will be
reported in an Euronext notice and in a specific communication on
AB Science’s website.
Investors are
invited to take note of the risks associated with this
transaction,
potentially dilutive
of 7.2% of the company’s share capital on the
basis of the capital after the capital increase announced on 24
April 2023, which could create
downward pressure on the AB Science share, as mentioned in
sections 6.4.4 and 6.4.6 of the 2022
annual report. Investors are also invited to be
vigilant before taking the decision to invest in a company that
carries out such operations, particularly when they are carried out
successively. AB Science recalls that the present dilutive
financing operation is not the first one it has put in
place.
Restructuring of convertible bonds
issued in February 2022 and Class C preferred shares
AB Science announced on 21 April 2023 the
negotiation of a framework agreement under which the terms and
conditions of the bond issue agreement (entered into with the
holders of the US$8.5 million convertible bonds issued in February
2022 and to which 50,000 warrants were attached with an exercise
price of 000 warrants with an exercise price of EUR 12.65) would be
amended to provide, on 15 July 2023 and automatically, for the
conversion of all the convertible bonds into ordinary shares of AB
Science on the basis of a price per share of EUR 5.75 (i.e. the
subscription price of the New Shares).
A framework agreement has also been negotiated
with the holders of Class C preferred shares (the
“C Preferred”). The C Preferred still in circulation would be
repurchased by AB Science for one symbolic euro (and subsequently
cancelled). 520,786 share warrants (each warrant entitling the
holder to subscribe for one ordinary share of AB Science at par
value for a period of 12 months) will be issued in substitution of
the C Preferred. In addition, still in substitution of the C
Preferred, a new class of preferred shares would be created,
benefiting from priority dividend rights (equal to 1.25% of the net
sales of masitinib or of any licensing royalties, up to a limit of
9.0 million euros) and convertible into 750,000 ordinary shares of
AB Science if the share price of AB Science exceeds a threshold of
30 euros for more than 90 consecutive days.
These agreements will be submitted to AB Science
shareholders for approval at the next annual general shareholders
meeting, Alain Moussy having declared that he was in favour of the
planned restructuring.
Finally, it will be proposed to the shareholders
to extend the term of certain lines of warrants already issued, to
adapt to the evolution of AB Science’s strategy and of its clinical
pipeline.
Decision of the Enforcement Committee of
the French market regulator (AMF) following the investigation
relating to the financial information and the market for AB Science
shares, opened in September 2017
On March 24, 2022, the AMF Enforcement Committee
ruled that there was no privileged information, neither at the time
of the two capital increases carried out by AB Science on March 24
and 27, 2017, nor at the time Alain Moussy sold a part of his
shares on March 31, 2017. The AMF Enforcement Committee therefore
completely exonerated Alain Moussy, prosecuted for insider trading,
and found that AB Science had not failed to comply with its
disclosure obligations at the time of these capital increases in
March 2017.
The AMF Enforcement Committee nevertheless
considered that AB Science should have communicated as early as
April 7, 2017 the high probability of a negative opinion from the
European Medicine Agency (EMA) on the marketing authorization
application for masitinib for the treatment of mastocytosis and
ordered AB Science to pay the sum of one million euros.
In application of its internal procedures, AB
Science had nevertheless put in place a deferral of privileged
information from this date of April 7, 2017, considering that the
delay in communication was in the interest of the Company and in
line with industry practices of not communicating before the final
vote of the CHMP, or else withdrawing the registration dossier,
which AB Science had no intention to do.
Given this difference in assessment concerning a
technical point relating to one of the criteria for the deferred
communication of privileged information, as well as the amount of
penalty, AB Science has decided to appeal to the Paris Court of
Appeal. The President of AMF also appealed against the Enforcement
Committee's decision. It concerns in particular the exoneration of
Alain Moussy.
Other
events
-
Autres opérations sur les valeurs mobilières
During the year 2022, the following were
granted:
- 183,040 share warrants, of which
50,000 were granted to a historical investor, 126,050 to the
European Investment Bank as part of the financing agreement and
6,990 to directors
- 5,000 stock-options to an
employee
AB Science confirms its eligibility for PEA-PME
(a share savings plan aimed at providing finance to SMEs) in
accordance with decree no. 2014-283 of 4 March 2014 taken for the
application of article 70 of law no. 2013-1278 of 29 December 2013
of finance for 2014 fixing the eligibility of companies for
PEA-PME, i.e. less than 5,000 employees on the one hand, an annual
turnover of less than 1.5 billion euros or a balance sheet total of
less than 2 billion euros, on the other hand.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, inflammatory diseases and viral
diseases. The company is headquartered in Paris, France, and listed
on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB
ScienceThis press release contains forward-looking
statements. These statements are not historical facts. These
statements include projections and estimates as well as the
assumptions on which they are based, statements based on projects,
objectives, intentions and expectations regarding financial
results, events, operations, future services, product development
and their potential or future performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents published by AB Science. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
- AB SCIENCE Resultats 2022 VENG VF
Ab Science (LSE:0Q77)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ab Science (LSE:0Q77)
Gráfica de Acción Histórica
De May 2023 a May 2024